{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:51:50Z","timestamp":1763470310793,"version":"3.45.0"},"reference-count":30,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Bromoepiandrosterone (BEA), a synthetic analog of the adrenal steroid DHEA, holds promise as a host-directed therapy for both active and latent tuberculosis (TB). Unlike DHEA, BEA lacks hormonal side effects yet retains potent immunomodulatory activity. It promotes a Th1-skewed immune response by enhancing interferon-\u03b3 (IFN-\u03b3) and tumor necrosis factor-\u03b1 (TNF-\u03b1), critical cytokines for macrophage activation and intracellular control of Mycobacterium tuberculosis (Mtb), while suppressing Th2 cytokines such as IL-4. BEA also inhibits 11\u03b2-hydroxysteroid dehydrogenase-1, lowering intracellular cortisol levels and reversing the local immunosuppression commonly seen in TB. These features enable BEA to restore immune competency in TB-infected tissues. In murine TB models, BEA halted bacterial growth, reduced pulmonary inflammation, and synergized with standard anti-TB drugs to enhance bacterial clearance. Additionally, DHEA and its analogues have demonstrated direct antimycobacterial activity, likely by interfering with Mtb mycolic acid synthesis, a property BEA is believed to share. For latent TB, BEA\u2019s ability to sustain Th1-mediated immunity and counteract immune suppression could help maintain latency and prevent reactivation, especially in immunocompromised individuals. By boosting immune surveillance and potentially contributing to bacillary clearance, BEA offers a unique adjunctive approach that complements existing TB treatments without contributing to drug resistance. Its dual function, an immune modulator and antimicrobial agent, supports its use across the TB disease spectrum. These properties position BEA as a novel candidate for host-directed therapy aimed at improving outcomes in both drug-sensitive and drug-resistant TB, as well as therapies aimed at enhancing long-term containment of latent infection.<\/jats:p>","DOI":"10.3390\/pathogens14111179","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:33:04Z","timestamp":1763469184000},"page":"1179","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proposing Bromo-Epi-Androsterone for Host-Directed Therapy Against Tuberculosis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-6101","authenticated-orcid":false,"given":"Coad Thomas","family":"Dow","sequence":"first","affiliation":[{"name":"McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI 53705, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam","family":"Obaid","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024). Global Tuberculosis Report 2024, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240101531."},{"key":"ref_2","unstructured":"World Health Organization (2024). Global Tuberculosis Report 2024\u2014Determinants, Risk Factors, and Treatment Outcomes, World Health Organization. Available online: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100522","DOI":"10.1016\/j.jctube.2025.100522","article-title":"Strengthening the global Response to Tuberculosis: Insights from the 2024 WHO global TB report","volume":"39","author":"Estaji","year":"2025","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Navasardyan, I., Miwalian, R., Petrosyan, A., Yeganyan, S., and Venketaraman, V. (2024). HIV-TB Coinfection: Current Therapeutic Approaches and Drug Interactions. Viruses, 16.","DOI":"10.3390\/v16030321"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Caraux-Paz, P., Diamantis, S., de Wazi\u00e8res, B., and Gallien, S. (2021). Tuberculosis in the Elderly. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245888"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Olmo-Font\u00e1nez, A.M., and Turner, J. (2022). Tuberculosis in an Aging World. Pathogens, 11.","DOI":"10.3390\/pathogens11101101"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Theodorakis, N., Feretzakis, G., Hitas, C., Kreouzi, M., Kalantzi, S., Spyridaki, A., Kollia, Z., Verykios, V.S., and Nikolaou, M. (2024). Immunosenescence: How Aging Increases Susceptibility to Bacterial Infections and Virulence Factors. Microorganisms, 12.","DOI":"10.3390\/microorganisms12102052"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e130090","DOI":"10.1172\/jci.insight.130090","article-title":"Cytomegalovirus infection is a risk factor for tuberculosis disease in infants","volume":"4","author":"Tanner","year":"2019","journal-title":"JCI Insight"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/infdis\/jiac179","article-title":"Association Between Cytomegalovirus Infection and Tuberculosis Disease: A Systematic Review and Meta-Analysis of Epidemiological Studies","volume":"227","author":"Kua","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5501\/wjv.v4.i1.17","article-title":"Mechanistic insights on immunosenescence and chronic immune activation in HIV-tuberculosis co-infection","volume":"4","author":"Shankar","year":"2015","journal-title":"World J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13052-025-02019-2","article-title":"Meta-analysis of TB & HIV co-infection mortality rate in sub-Saharan African children, youth, and adolescents","volume":"51","author":"Bizuneh","year":"2025","journal-title":"Ital. J. Pediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1006\/frne.2001.0216","article-title":"DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology","volume":"22","author":"Labrie","year":"2001","journal-title":"Front. Neuroendocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/ageing\/afp015","article-title":"The association between dehydroepiandosterone and frailty in older men and women","volume":"38","author":"Voznesensky","year":"2009","journal-title":"Age Ageing"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/aid.2006.0170","article-title":"Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: A randomized placebo-controlled study","volume":"23","author":"Abrams","year":"2007","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1917","article-title":"Interleukin-6 and chronic inflammation","volume":"8","author":"Gabay","year":"2006","journal-title":"Arthritis Res Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1210\/jcem-17-9-1051","article-title":"Dehydroepiandrosterone and androsterone levels in human plasma: Effect of age and sex; day-to-day and diurnal variations","volume":"17","author":"Migeon","year":"1957","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","first-page":"1360","article-title":"Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age","volume":"78","author":"Morales","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1139\/H08-013","article-title":"Impact of DHEA(S) and cortisol on immune function in aging: A brief review","volume":"33","author":"Buford","year":"2008","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0090-1229(05)80024-8","article-title":"Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells","volume":"61","author":"Suzuki","year":"1991","journal-title":"Clin. Immunol. Immunopathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0024-3205(92)90204-3","article-title":"Adrenal glands of mouse and rat do not synthesize androgens","volume":"50","author":"Bierings","year":"1992","journal-title":"Life Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/carcin\/2.7.683","article-title":"Dehydroepiandrosterone and 16 alpha-bromo-epiandrosterone: Inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes","volume":"2","author":"Henderson","year":"1981","journal-title":"Carcinogenesis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/10253890.2022.2164187","article-title":"Measuring stress: A review of the current cortisol and dehydroepiandrosterone (DHEA) measurement techniques and considerations for the future of mental health monitoring","volume":"26","author":"Ahmed","year":"2023","journal-title":"Stress"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4269\/ajtmh.2007.76.232","article-title":"Reduction of parasite levels in patients with uncomplicated malaria by treatment with HE2000","volume":"76","author":"Frincke","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1016\/j.bmc.2010.05.008","article-title":"16-bromoepiandrosterone, an activator of the mammalian immune system, inhibits glucose 6-phosphate dehydrogenase from Trypanosoma cruzi and is toxic to these parasites grown in culture","volume":"18","author":"Cordeiro","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1086\/426453","article-title":"16alpha-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis","volume":"191","author":"Orozco","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cei.13603","article-title":"16\u03b1-Bromoepiandrosterone as a new candidate for experimental diabetes-tuberculosis co-morbidity treatment","volume":"205","author":"Yepez","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2249.2009.04032.x","article-title":"16alpha-Bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs","volume":"158","author":"Nicoletti","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1469-0691.2006.01520.x","article-title":"Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000)","volume":"12","author":"Reading","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1128\/AAC.01446-06","article-title":"Safety and activity of the immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients","volume":"51","author":"Stickney","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Dow, C.T., and Obaid, L. (2025). Proposing Bromo-Epi-Androsterone (BEA) for Post-Traumatic Stress Disorder (PTSD). Cells, 14.","DOI":"10.3390\/cells14141120"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/11\/1179\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:48:09Z","timestamp":1763470089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/11\/1179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["pathogens14111179"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14111179","relation":{},"ISSN":["2076-0817"],"issn-type":[{"type":"electronic","value":"2076-0817"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}